First Hospital of Quanzhou Affiliated to Fujian Medical University, 362000 Quanzhou, People's Republic of China.
The Teaching Hospital of Fujian Medical University, Fujian Provincial Cancer Hospital, 350000 Fuzhou, People's Republic of China.
Cancer Radiother. 2023 May;27(3):189-195. doi: 10.1016/j.canrad.2022.09.001. Epub 2023 Feb 6.
For treatment of esophageal carcinoma, the optimal postoperative radiotherapy target volume after three-field lymph node dissection (3-FLD) had not been determined. We analyzed local recurrence pattern of thoracic esophageal carcinoma and risk factors of lymph node recurrence after 3-FLD without prophylactic radiotherapy.
We reviewed 1282 patients with thoracic esophageal squamous cell carcinoma (ESCC) who were treated with 3-FLD without radiotherapy from 2010 to 2018 and analysed local recurrence patterns and risk factors of lymph node recurrence, in order to provide a reference for determination of the radiotherapy target volume for thoracic ESCC.
The lymph node recurrence accounted for 91.0% of treatment failures. The mediastinal, cervical and abdominal lymph node recurrence accounted for 84.92%, 36.07% and 22.30%, respectively (χ=264.776, P=0.000). The superior, middle and inferior mediastinal lymph node recurrence rates were 67.54%, 27.87% and 0.98%, respectively (χ=313.600, P=0.000). Cervical metastases were significantly associated with N stage and Preoperative cervical lymph node status. Abdominal metastases were significantly associated with the number of preoperative abdominal lymph node metastases (LNM), tumor location and N stage.
The main pattern of local-regional recurrence might be lymph node metastasis after radical 3-FLD without radiotherapy in esophageal carcinoma. The dangerous lymph node recurrence regions included neck, superior and middle mediastinum. The abdominal areas might be irradiated for lower TEC patients with preoperative abdominal LNM.
对于食管癌的治疗,在进行三野淋巴结清扫(3-FLD)后,最佳的术后放疗靶区尚未确定。我们分析了未行预防性放疗的 3-FLD 后胸段食管鳞癌(ESCC)的局部复发模式和淋巴结复发的危险因素。
我们回顾了 2010 年至 2018 年间,1282 例接受 3-FLD 治疗但未接受放疗的胸段 ESCC 患者,分析了局部复发模式和淋巴结复发的危险因素,以期为胸段 ESCC 的放疗靶区确定提供参考。
淋巴结复发占治疗失败的 91.0%。纵隔、颈部和腹部淋巴结复发分别占 84.92%、36.07%和 22.30%(χ²=264.776,P=0.000)。上、中、下纵隔淋巴结复发率分别为 67.54%、27.87%和 0.98%(χ²=313.600,P=0.000)。颈部转移与 N 分期和术前颈部淋巴结状态显著相关。腹部转移与术前腹部淋巴结转移(LNM)的数量、肿瘤位置和 N 分期显著相关。
根治性 3-FLD 后不进行放疗的食管癌主要局部复发模式可能是淋巴结转移。危险的淋巴结复发区域包括颈部、上纵隔和中纵隔。对于术前有腹部 LNM 的低 T 期 ESCC 患者,腹部区域可能需要进行放疗。